希力新冲剂对恶性肿瘤放射治疗的临床与实验观察

Clinical and Experimental observation of Xilixin Granule Combined with Radiotherapy in Treating Malignant Tumors

用希力新冲剂配合放射治疗鼻咽癌、肺癌３６例（治疗组），与放疗加贞芪扶正冲剂治疗３１例（对照组）比较，临床阴虚症状明显好转；治疗组的白细胞下降为５．６％，而对照组达２５．８％；３年存活率治疗组（７５．０％）明显优于对照组（５１．６％）。动物实验显示希力新冲剂对肿瘤有明显的抑制作用，对白细胞、血小板和血红蛋白均有提升作用，大剂量组尤为明显。提示希力新冲剂对恶性肿瘤的放射治疗损伤可能具有一定的防护作用。

Thirty six patients of pulmonary or nasopharyngeal carcinoma were treated with Xilixin granule (XLXG) combined with radiotherapy and compared their efficacy with that of 31 patients treated by Zhenqi Fuzheng granule combined with radiotherapy for control. Results showed that the symptoms of Yin Deficiency syndrome in treated group were obviously improved, the leucocyte decreased by 5.6%, while in control group it reached 25.8%,the 3 year survival rate was significantly higher in treated group (75.0%) than that in control group (51.6%).Animal experiment revealed that XLXG had the effects of tumor inhibition,it could increase white blood cells, platelets and hemoglobin of patients,especially in using large dosage. These results suggested that XLXG have some protective effect against radiotherapeutic damage in patients with malignant tumor.